Revisiting long-term adherence to highly active antiretroviral therapy in senegal using latent class analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 1, 2011, Pages 55-61

  Bastard, Mathieu ^a,b,c,d,g   Fall, Mame Basty Koita ^e   Lanièce, Isabelle ^e   Taverne, Bernard ^f   Desclaux, Alice ^g   Ecochard, René ^a,b,c,d   Sow, Papa Salif ^e   Delaporte, Eric ^f   Etard, Jean François ^f  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^e Centre Hospitalier Universitaire Dakar   (Senegal)

^f INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^g EPICENTRE   (France)

Author keywords

adherence; antiretroviral therapy; latent class analysis; mixed model; Senegal; women

Indexed keywords

COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SENEGAL; SURVIVAL; TREATMENT DURATION;

EID: 79955013695     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318211b43b     Document Type: Article

References (51)

1. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300:51-59. (Pubitemid 351920404)
2. Safeguarding the future of HIV/AIDS initiatives. Lancet Infect Dis. 2009; 9:521.
3. Desclaux A, Ciss M, Taverne B, et al. Access to antiretroviral drugs and AIDS management in Senegal. AIDS. 2003;17(suppl 3):S95-S101. (Pubitemid 36951675)
4. Kebba A. Antiretroviral therapy in sub-Saharan Africa: myth or reality? J Antimicrob Chemother. 2003;52:747-749. (Pubitemid 37407800)
5. World Health Organization. AIDS epidemic update. 2009.Available at: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/ jc1700-epi-update-2009-en.pdf. Accessed June 30, 2010.
6. Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53:558-561. (Pubitemid 38499767)
7. Zachariah R, Ford N, Philips M, et al. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2009;103:549-558.
8. Bangsberg DR, Machtinger EL. Adherence to HIV antiretroviral therapy. 2006. Available at: http://hivinsite.ucsf.edu/InSite?page=kb-03-02-09. Accessed June 30, 2009.
9. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15: 1181-1183. (Pubitemid 32549871)
10. Castro A. Adherence to antiretroviral therapy: merging the clinical and social course of AIDS. PLoS Med. 2005;2:e338.
11. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:e438.
12. World Health Organization. Adherence to Long-Term Therapy: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003. Available at: http://apps.who.int/medicinedocs/en/d/Js4883e/. Accessed July 6, 2009.
13. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S123-S127. (Pubitemid 35453571)
14. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr. 2001;28:232-239. (Pubitemid 33055448)
15. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599-1605. (Pubitemid 30129133)
16. Desclaux A, Lanièce I, Ndoye I, et al. The Senegalese Antiretroviral Drug Access Initiative. An Economic, Social, Behavioural and Biomedical Analysis. Paris, France: ANRS, UNAIDS, WHO; 2002.
17. Etard JF, Laniece I, Fall MB, et al. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Trop Med Int Health. 2007;12:1191-1198. (Pubitemid 47628574)
18. Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. 2003; 17(suppl 3):S103-S108. (Pubitemid 36951676)
19. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189. (Pubitemid 43786107)
20. Tobin J. Estimation of relationships for limited dependent variables. Econometrica. 1958;26:24-36.
21. Twisk J, Rijmen F. Longitudinal tobit regression: a new approach to analyze outcome variables with floor or ceiling effects. J Clin Epidemiol. 2009;62:953-958.
22. Skrondal A, Rabe-Hesketh S. Generalized Latent Variable Modeling: Multilevel, Longitudinal and Structural Equation Models. Boca Raton, FL: Chapman & Hall/CRC; 2004.
23. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. 2nd ed. College Station, TX: Stata Press; 2008.
24. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296:679-690. (Pubitemid 44200639)
25. Abaasa AM, Todd J, Ekoru K, et al. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res. 2008;8:241.
26. Diabate S, Alary M, Koffi CK. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d'Ivoire. AIDS. 2007;21:1799-1803. (Pubitemid 47237568)
27. Byakika-Tusiime J, Crane J, Oyugi JH, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009;13(suppl 1):82-91.
28. Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010;5:e10584.
29. Salmon-Ceron D, Deleuze J, Coste J, et al. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients]. Ann Med Interne (Paris). 2000;151:297-302. (Pubitemid 30645104)
30. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
31. Tanon AK, Eholie SP, Polneau S, et al. [Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)]. Med Mal Infect. 2008;38:264-269.
32. Biadgilign S, Deribew A, Amberbir A, et al. Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia. BMC Pediatr. 2008;8:53.
33. Mellins CA, Brackis-Cott E, Dolezal C, et al. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004; 23:1035-1041. (Pubitemid 40824294)
34. Desmond Tutu HIV Foundation. Adult HIV: A learning programme for professionals. 2007. Available at: http://ebwhealthcare.com/pdf/AdultHIV\- OnlineEdition.pdf. Accessed July 10, 2009.
35. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
36. Kempf MC, Pisu M, Dumcheva A, et al. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr. 2009;52:336-341.
37. Bila B, Egrot M. Gender asymmetry in healthcare-facility attendance of people living with HIV/AIDS in Burkina Faso. Soc Sci Med. 2009;69:854-861.
38. Desclaux A, Msellati P, Walentowitz S. Women, mothers and HIV care in resource-poor settings. Soc Sci Med. 2009;69:803-806.
39. Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt). 2008;17:47-55. (Pubitemid 351197536)
40. Remien RH, Chowdhury J, Mokhbat JE, et al. Gender and care: access to HIV testing, care, and treatment. J Acquir Immune Defic Syndr. 2009; 51(suppl 3):S106-S110.
41. Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2010;54:197-203.
42. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006; 43:78-84. (Pubitemid 44306492)
43. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006; 296:782-793. (Pubitemid 44223102)
44. Crane JT, Kawuma A, Oyugi JH, et al. The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav. 2006;10:437-442. (Pubitemid 44174972)
45. Nwauche C, Erhabor O, Ejele O, et al. Adherence to antiretroviral therapy among HIV-infected subjects in a resource-limited setting in the Niger Delta of Nigeria. Afr J Health Sci. 2006;13:13-17.
46. Rosen S, Ketlhapile M, Sanne I, et al. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J. 2007;97:524-529. (Pubitemid 47091191)
47. Wakabi W. Low ART adherence in Africa. Lancet Infect Dis. 2008;8:94.
48. Costagliola D, Barberousse C. Comment mesurer l'observance? In: Bessette D, Bungener M, Costagliola D, Flori YA, Matheron S, Morin M, Setbon M, Souteyrand Y, editors. L'observance aux traitements contre le VIH/sida: mesure, déterminants, évolution. Collection sciences sociales et sida. Paris: ANRS, 2002;33-42.
49. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21: 1074-1090; discussion 1073. (Pubitemid 29326165)
50. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis. 2001;33:865-872. (Pubitemid 32831844)
51. De Beaudrap P, Etard JF, Ecochard R, et al. Change over time of mortality predictors after HAART initiation in a Senegalese cohort. Eur J Epidemiol. 2008;23:227-234.